Cerebellar Neuroblastoma in 2.5 Years Old Child

Total Page:16

File Type:pdf, Size:1020Kb

Cerebellar Neuroblastoma in 2.5 Years Old Child Case Report Cerebellar Neuroblastoma in 2.5 Years Old Child Mohammad Pedram1, Majid Vafaie1, Kiavash Fekri1, Sabahat Haghi1, Iran Rashidi2, Chia Pirooti3 Abstract 1. Thalassemia and Neuroblastoma is the third most common malignancy of childhood, after leukemia Hemoglobinopathy Research Center, Ahvaz Jondishapur University of and brain tumors. Only 2% of all neuroblastoma occur in the brain. Primary Medical Sciences, Ahvaz, Iran cerebellar neuroblastoma is an specific subset of Primitive Neuroectodermal 2. Dept. of Pathology, Shafa Tumors (PNET). Meduloblastoma is a relatively common and well-established Hospital , Ahvaz Jondishapur entity, consisting of primitive and multipotential cells that may exhibit some University of Medical Sciences, evidence of neuroblastic or gliad differentiation. But cerebellar neuroblastoma Ahvaz, Iran with ultrastractural evidence of significant neuroblastic differentiation is 3. Dept. of Neurosurgery, Golestan extremely rare. We report a rare case of neuroblastoma in the cerebellum. A Hospital, Ahvaz Jondishapur 2.5-year-old Iranian boy presented with vomiting and nausea in the morning and University of Medical Sciences, ataxia. CT scan showed a tumor mass in the cerebellum and the report of Ahvaz, Iran radiologist was medulloblastoma. Light microscopic assay showed a small cell Corresponding Author: neoplasm with lobules of densely packed cells (lobulated pattern) and better Mohammad Pedram, MD; differentiated cells. Neuron-Specific Enolase was positive. Pathologic diagnosis Professor of Pediatrics Hematology- confirmed the existence of cerebellar neuroblastoma. Chemotherapy followed Oncology surgical removal. No relapse occurred 12 months after surgery. Tel: (+98) 611 374 32 85 Email: Keywords: Neuroblastoma; Cerebellum; Chemotherapy [email protected] Please cite this article as: Pedram M, Vafaie M, Fekri K, Haghi S, Rashidi I, Pirooti Ch. Cerebellar Neuroblastoma in 2.5 Years Old Child. Iran J Cancer Prev. Received: 2 Jan. 2012 2013; 6(3):174-6. Accepted: 18 Feb. 2012 Iran J Cancer Prev 2013;3:174-6 Introduction Neroblastoma is the most common extracranial site of cerebellum, the tumor maybe classified as solid tumor in children, accounting for 8% to 10% of cerebellar ganglioneuroblastoma. all childhood cancers [1-4]. When they form a lobulated pattern with cells A tumor mass can occur anywhere along the streaming in a fine fibrillated background, they are sympathetic nerve crest pathway [2]. designated cerebellar neuroblastoma [1, 7, 8]. Therefore, a wide variety of tumor locations and Review of epidemiologic studies and case reports clinical presentations have been described [5] but revealed that there is not a reported case of only 2% of all nerublastoma arise in the brain [6]. cerebellar neuroblastoma as a primary CNS tumor in The most common malignant brain tumor of childhood Iran [9-11]. Here, we describe a rare case with is Medulloblastoma [1, 2]. Medulloblastoma, cerebellar mass, which pathological diagnosis was medullophithelioma, and neuroblastoma are cerebellar neuroblastoma. designated in the WHO classification as embryonic and cytologically pluripotential tumors. Case Report Microscopically, medulloblastomas exhibit highly We report a patient with primary cerebellar variable histological features, most frequently neuroblastoma. A 2.5-year-old boy was admitted to appearing as an infiltrative, extremely our hospital because of nausea and vomiting in the undifferentiated, cellular neoplasm [3, 5]. The cells morning, headache, ataxia, poor balance and have carrot - shaped or ovoid nuclei with course torticulli. The preoperative routine complete blood dark chromatin and scant or no visible cytoplasm. count , clotting profiles , electrolytes , sequential Mitoses and necrosis are highly variable. Homer – multiple analysis for chemistry , and the urine wright rosettes, the core of which is formed or analysis findings were all within the normal limits . A tenuous fibrillated processes, may be present. brain CT scan revealed a well defined hyperdense Exceptionally, neurons in various stages of maturation mass in cerebellar vermis compressing forth ventricle are observed. When matured cells are present at the with obstructive hydrocephaly, compatible with medulloblastoma (Figure 2). A microscopic Vol 6, No 3, Summer 2013 174 Cerebellar Neuroblastoma in 2.5 Years Old Child suboccipital craniectomy was performed and after During this hospital admission, postoperative systemic complete resection of the tumor, a examinnation which included bone survey, bone ventriculoperitoneal shunt was inserted. marrow aspiration, abdomino-pelvic CT scan and The pathologist reported a lesion composed of small, MRI of the neuroaxis revealed no other evidence of dense and round cells with hyperchromatic nucleus tumor. Also cytologgical examination of cerebrospinal and scanty cytoplasm. The lesion arranged in sheets fluid was normal. After surgery we began and prevascular accumulation numerous foci of small chemotherapy with a combination of Cisplatin, Ara-c, cells with few mitotic figures. There were necrosis and Vincristine, Hydroxyurea, Lamustin, Procarbazin, hemorrhagia. Also lobulated tumor cells were Cyclophosphamide and Methyl prednisolon (8 at 1 arranged in groups (islands separated by few protocol) every four weeks for 12 courses. Follow up fibrous stroma). Parallel patterns were seen in some examinnation revealed a profound delay in mental foci of tumor cells. Also cells with vesicular nuclei development but brain MRI performed 12 months were seen (Figure 2). These findings established the after surgery revealed no evidence of tumor diagnosis of neuroblastoma. Immuno-Histo-Chemistry recurrence. The patient is presently 3.5 years old (IHC) showed a strong positivity for Neuron-Specific and his chemotherapy is finished and he is stable Enolase (NSE). with no sign of relapse. Figure 1.This figure shows Figure 2. This figure shows pathological slide brain CT scan at the time of diagnosis. of tumor (H&E staaining). Discussion researchers have not observed the ultrastructural Neuroblastoma is an enigmatic tumor in its clinical characteristics of neuronal differentiation in and biologic behavior [1]. Emberyonal tumors or medulloblastoma [13]. Yagishita et al. examined a Primitive Neuroectodermal Tumors ( PNET ) are the series of medulloblastomas by histological and most common groups of malignant CNS tumors of immunohistochemical techniques and proposed the childhood , accounting for 20 – 25 % of pediatric hypothesis that meedulloblastoma was a stem – cell CNS tumors [3]. Primitive neuroepithelial tumors of lines, astrocytic, ependymall, neuronal and the CNS, with few or absent foci of cellular oligoddendroglial although "cerebellar differentiation, are called primary cerebral neuroblastoma" could arise from differentiation of a neuroblstoma or medulloblastoma depending on a medulloblastoma along neuroblastic lines [14,15]. supra – or infratentorial location of the mass, Cerebellar "neuroblastomas" are extremely rare respectively [1]. A wide variety of tumors are known [15]. There are a few reports of cerebellar to occur in the cerebellum and many of these are neuroblastoma in the papers. Shuji Nishio et al. referred to as medulloblastoma [12]. (2000) reported a case of cerebellar neuroblastoma Medulloblastoma, accounting for 90% of embryonal in an infant separately. This tumor displays a better tumors, is a cerebellar tumor [4]. Their cells are prognosis than thoose with classical or desmoplastic primitive or poorly differentiated and are medulloblastoma. The optimal treatment for patients considered to be of embryonic origin [13]. Its with this tumor, however, remains uncertain. This differentiating capacity is one of disputes. Many tumor tends to occur in young children particuularly in Vol 6, No 3, Summer 2013 175 Pedram et al. infants, and this further makes the treatment 5. Tatis N, Tavuz M, Reis A. primary cerebral problematic [16]. Our patient was treated by total neuroblastoma : a case Treated with adjuvant removal of the tumor followed by chemotherapy. He chemotherapy and radiotherapy . The Turkish Journal of was survived one year after operation without pediatrics. 2004; 46: 182-5. recurrence. 6. Polat P, Kuntarci M, Eren S, Suma S. Primary cerebral neuroblastoma. JBR-BTR. 2005; 66: 148- 9. 7. Powers JM, Horoupian D. Disease of the nervous Acknowledgment system and sensory organs : Anderson's pathology. Ten th We appreciate all staff in oncology ward of edition. Mosby. 1996; 26: 93 -2831. Shafa Hospital, neurosurgery ward in Golestan 8. Brandis A, Heyer R, Hori A, Walter GF. Hospital, Dr. Iran Rashidi in pathological laboratory cerebellarneuroblastoma :An important differential of Shafa Hospital and Dr. Kaveh jaseb in Shafa diagnosis from cerebellar neuroblastoma and medulloblastoma. Neuropediatrics 1997; 28(4): 235- 8. oncology ward. 9. Alimohamadi SM, Ghodsi SM, Ketabchi SE. Epidemiologic patterns of primary brain tumors in Iran. Conflict of Interest Asian Pac J Cancer Prev. 2008 Apr-Jun; 9(2):361-2. There is no conflict of interest in this study. 10. Mehrazin M, Rahmati H,Yavari P. Epidemiology of primary intracranial tumors in Iran, 1978-2003. Asian Pac J Cancer Prev. 2006 Apr-Jun; 7(2):283-8. Authors' Contribution 11. Miabi Z, Midia M, Midia R. EVALUATION OF Majid Vafaei wrote the case report. Kiavash Fekri PEDIATRIC INTRACRANIAL NEOPLASM IN TABRIZ, IRAN. and Sabahat Haghi contributed to the literature Acta Medica Iranica. 2007; 45(6):458-65. review, discussion and patient follow
Recommended publications
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: an Overview Comparing Pediatric and Adult Populations
    cancers Review Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations 1, 2, 2 3 Aline Rangel-Pozzo y, Luiza Sisdelli y, Maria Isabel V. Cordioli , Fernanda Vaisman , Paola Caria 4,*, Sabine Mai 1,* and Janete M. Cerutti 2 1 Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [email protected] 2 Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo/EPM, São Paulo, SP 04039-032, Brazil; [email protected] (L.S.); [email protected] (M.I.V.C.); [email protected] (J.M.C.) 3 Instituto Nacional do Câncer, Rio de Janeiro, RJ 22451-000, Brazil; [email protected] 4 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy * Correspondence: [email protected] (P.C.); [email protected] (S.M.); Tel.: +1-204-787-2135 (S.M.) These authors contributed equally to this paper. y Received: 29 September 2020; Accepted: 26 October 2020; Published: 27 October 2020 Simple Summary: Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence clinical and biological behavior in both children and adults. In this review, we focus on the comparison between pediatric and adult PTC, highlighting genetic alterations, telomere-related genomic instability and changes in nuclear organization as novel biomarkers for thyroid cancers. Abstract: Thyroid cancer is a rare malignancy in the pediatric population that is highly associated with disease aggressiveness and advanced disease stages when compared to adult population.
    [Show full text]
  • 493.Full.Pdf
    THE MERICAN JOURNAL OF CANCER A Continuation of The Journal of Cancer Research VOLUMEXXXVI I DECEMBER,1939 NUMBER4 GLIOMAS IN ANIMALS A REPORTOF Two ASTROCYTOMASIN THE COMMONFOWL ERWIN JUNGHERR, D.M.V., AND ABNER WOLF, M.D. (From the Department of Animal Diseases, Storrs Agricultural Experiment Station; the Department of Neuropathology, Columbia University; the Neurological Institute of New York) In one of the first modern studies of comparative tumor pathology, Bland- Sutton (4) stated that ‘‘ no tumors are peculiar to man.” While this view was supported in general by subsequent observations, the infreqhent reports of gliomas and other tumors of the central nervous system in animals other than man seemed to be significant. This low incidence, however, is probably more apparent than real. In a recent dissertation on the subject, Grun (20) points out that post-mortem examination of the brain in animals is performed com- paratively infrequently and that possible carriers of tumors of the central nerv- ous system are often disposed of by slaughter without adequate study. Enhanced interest in the study of brain tumors in man has been reflected in the increased number of reports of cerebral neoplasms in animals, espe- cially during the past decade, but many of these cases have been so inade- quately described that even an approximate classification is difficult. There is thus a definite need for wider information on the comparative pathology of tumors of the nervous system. The present communication aims to contribute to the subject by a brief critical review of the literature on gliomas in the lower animals, and by the reports of two additional cases in the common fowl.
    [Show full text]
  • Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
    International Journal of Molecular Sciences Review Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies 1, 2, 2 2, Kinga B. Stopa y , Agnieszka A. Kusiak y, Mateusz D. Szopa , Pawel E. Ferdek * and Monika A. Jakubowska 1,* 1 Malopolska Centre of Biotechnology, Jagiellonian University, ul. Gronostajowa 7A, 30-387 Krakow, Poland; [email protected] 2 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Krakow, Poland; [email protected] (A.A.K.); [email protected] (M.D.S.) * Correspondence: [email protected] (P.E.F.); [email protected] (M.A.J.) These authors contributed equally to this work. y Received: 9 April 2020; Accepted: 29 April 2020; Published: 1 May 2020 Abstract: Pancreatic ductal adenocarcinoma (PDAC) causes annually well over 400,000 deaths world-wide and remains one of the major unresolved health problems. This exocrine pancreatic cancer originates from the mutated epithelial cells: acinar and ductal cells. However, the epithelia-derived cancer component forms only a relatively small fraction of the tumor mass. The majority of the tumor consists of acellular fibrous stroma and diverse populations of the non-neoplastic cancer-associated cells. Importantly, the tumor microenvironment is maintained by dynamic cell-cell and cell-matrix interactions. In this article, we aim to review the most common drivers of PDAC. Then we summarize the current knowledge on PDAC microenvironment, particularly in relation to pancreatic cancer therapy. The focus is placed on the acellular stroma as well as cell populations that inhabit the matrix.
    [Show full text]
  • Risk Factors for Neuroblastoma
    cancer.org | 1.800.227.2345 Neuroblastoma Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that increases your chances of getting a disease such as cancer. Learn more about the risk factors for neuroblastoma. ● Risk Factors for Neuroblastoma ● What Causes Neuroblastoma? Prevention The risk of many adult cancers can be reduced with certain lifestyle changes , but at this time there are no known ways to prevent most cancers in children. The only known risk factors for neuroblastoma cannot be changed. There are no known lifestyle-related or environmental causes of neuroblastoma at this time. ● Can Neuroblastoma Be Prevented? Risk Factors for Neuroblastoma A risk factor is anything that increases the chances of getting a disease such as cancer. Different types of cancer have different risk factors. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Lifestyle-related risk factors such as body weight, physical activity, diet, and the use of tobacco and alcohol play a major role in many adult cancers. But these factors usually take many years to influence cancer risk, and they are not thought to play much of a role in childhood cancers, including neuroblastomas. No environmental factors (such as being exposed to chemicals or radiation during the mother’s pregnancy or in early childhood) are known to increase the chance of getting neuroblastoma. Age Neuroblastoma is most common in infants and very young children. It is very rare in people over the age of 10 years. Heredity Most neuroblastomas do not seem to run in families. But in about 1% to 2% of cases, children with neuroblastoma have a family history of it.
    [Show full text]
  • Pancreatic Neuroendocrine Tumours in Patients with Von Hippel-Lindau Disease
    Review Endokrynologia Polska DOI: 10.5603/EP.a2020.0027 Volume/Tom 71; Number/Numer 3/2020 ISSN 0423–104X Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease Agnieszka Zwolak1, 2, Joanna Świrska1, 2, Ewa Tywanek1, 2, Marta Dudzińska1, Jerzy S. Tarach2, Beata Matyjaszek-Matuszek2 1Chair of Internal Medicine and Department of Internal Nursing, Medical University in Lublin, Poland 2Department of Endocrinology, Medical University in Lublin, Poland Abstract Von Hippel-Lindau disease is a highly penetrant autosomal genetic disorder caused by a germline mutation in the tumour suppressor gene, manifesting with the formation of various tumours, including neuroendocrine tumours of the pancreas. The incidence of the latter is not very high, varying from 5% to 18%. To compare, haemangioblastomas and clear cell renal carcinoma are present in 70% of von Hippel-Lindau patients and are considered the main prognostic factors, with renal cancer being the most common cause of death. However, pancreatic neuroendocrine tumours should not be neglected, considering their malignant potential (different to sporadic cases), natural history, and treatment protocol. This paper aims to review the literature on the epidemiology, natural history, treatment, and surveillance of individuals affected by pancreatic neuroendocrine tumours in von Hippel-Lindau disease. (Endokrynol Pol 2020; 71 (3): 256–259) Key words: pancreatic neuroendocrine tumours; von Hippel-Lindau disease REVIEW Introduction 52 VHL patients evaluated by Hough, there were six people (12%) in whom pancreatic involvement was the Von Hippel-Lindau disease (VHL) is a highly penetrant only abdominal manifestation of the disease [9]. Fur- autosomal genetic disorder caused by a germline muta- thermore, in the study by Hammel, VHL disease was tion in the VHL tumour suppressor gene located on the diagnosed accidently in 6% of patients during imaging short arm of chromosome 3.
    [Show full text]
  • Genetics and the Etiology of Childhood Cancer
    Pediat. Res. 10: 513-517 (1976) Genetics and the Etiology of Childhood Cancer ALFRED G. KNUDSON, JR.13" Graduate School of Biomedical Sciences, University of Texas Health Science Center, Housron, Texas, USA In developed nations cancer is now the principal cause of death had bilateral disease; in fact, in the latter case, transmission fits a from disease between infancy and adulthood, yet little is known of dominant gene model. However, the affected offspring of unilat- its etiology. The most uniquely childhood tumors occur so soon eral cases are more often bilaterally affected than not, as with the after birth in many instances that prenatal initiation becomes affected offspring of bilateral cases. The simplest model which suspect. In all parts of the world, each form is uncommon, and, explains these observations is one which estimates that approxi- with a few notable exceptions, there is no region with a unique or mately 40% of cases are attributable to a dominant gene which very unusual incidence of a particular form. In studying the produces a mean number of 3 retinoblastomas/gene carrier, and etiology of childhood cancer we, begin by suspecting rather that it is a matter of chance whether a given individual acquires universal agents and processes. bilateral or unilateral disease, or, in fact, no disease, as an estimated 5% of carriers seem to do (9). On the other hand, 60% of WILMS' TUMOR cases occur in children who do not carry such a dominant gene; for these, tumor is a very improbable event and would virtually never Of all the childhood cancers none has a more uniform incidence occur bilaterally.
    [Show full text]
  • Mental and Seizure Manifestations in Relation to Brain Tumors a Statistical Study
    166 EPlLEPSlA Mental and Seizure Manifestations in Relation to Brain Tumors A Statistical Study A. GUVENER, B. K. BAGCHI, K. A. KO01 AND H. D. CALHOUN The Electroencephalographic Laboratory, Neuropsychiatric Institute, University of Michigan Medical Center, Ann Arbor, Mich. (U.S.A.) INTRODUCTION It is well known that mental or behavioral changes and seizures occur in some phases of the development of many tumors. Many investigators in reporting large series (300 or over) have given the frequency of the clinical manifestations and their relation- ships to areas and types of tumors (2, 4, 5, 9, 10, 12-15, 17, 20, 22, 24, 27, 31). It is not always clear why some tumors produce the above mentioned manifestations and others of Lhe same type, same location and about the same size do not. We thought it might be of interest to make a statistical evaluation of the interrelationships between three variables, tumor location, tumor type, increased intracranial pressure in respect to mental and seizure manifestations. In the literature these relationships are not always clearly given. These might have some bearing on the mechanism of the clinical changes. MATERIAL AND METHODS Out of 901 brain tumor entries in the EEG Laboratory file with EEG and clinical data only 326 have been selected for this report. The excluded ones are the following: all 359 brain tumor entries before 1950, in addition to a total of 167 metastatic, brain stem and posterior fossa tumors, and 49 tumors with incomplete clinical and EEG information. Out of the accepted 326 cases gross and microscopic autopsy findings were available in 62.
    [Show full text]
  • Localization and Treatment of Familial Malignant Nonfunctional Paraganglioma with Iodine-131 MIBG: Report of Two Cases
    Localization and Treatment of Familial Malignant Nonfunctional Paraganglioma with Iodine-131 MIBG: Report of Two Cases F. Khafagi, J. Egerton-Vernon, T. van Doom, W. Foster, I. B. McPhee, and R. W. G. Allison Departments of Endocrinology. Nuclear Medicine, Physical Sciences, Vascular Surgery, Orthopedic Surgery and Queensland Radium Institute, Royal Brisbane Hospital, Brisbane, A itstralia Two cases of familial, malignant, nonfunctional paraganglioma are reported. Uptake of iodine- 131 metaiodobenzylguanidine ([131I]MIBG) by the tumors and métastaseswas demonstrated. In the first case, with multicentric and locally invasive disease, [131I]MIBG correctly localized a right carotid body paraganglioma which had been missed arteriographically. In the second case, with widespread, symptomatic metastatic disease, a therapeutic dose of [131I]MIBG produced palliation of bone pain after the failure of radio- and chemotherapy. Uptake of [131I] MIBG by paragangliomas does not correlate with catecholamine secretory activity, lodine-131 MIBG should be considered as a therapeutic option in unresectable, malignant paragangliomas which take up this radiopharmaceutical. J NucíMed 28:528-531,1987 . aragangliomas are tumors arising from extra-adre found a place in localization not only of pheochromo nal paraganglion tissue, an extensive, multicentric sys cytomas but also of neuroblastomas (6), carcinoid tu tem ofhistologicallyand ultrastructurally similar organs mors (7), and medullary carcinoma of the thyroid (8). (paraganglia). Paraganglia can be shown to contain It is also being used to treat malignant pheochromocy small amounts of catecholamine and are best classified toma (9) and neuroblastoma (6). More recently, uptake according to their sites of origin; they are designated of [I3II]MIBG has been reported in nonfunctional par "functional" or "nonfunctional" according to whether agangliomas (70,77).
    [Show full text]
  • Opsoclonus-Myoclonus Surgical Outcome and Their Disorder
    COMMENT. All children with neuroblastoma and opsoclonus-myoclonus and ataxia had an excellent surgical outcome and their eye movement disorder eventually responded to ACTH. The majority have long-term learning and behavioral problems, requiring special remedial education and behavioral intervention. Immunizations should be delayed or withheld when possible to avoid relapse of opsoclonus and ataxia. CRANIOPHARYNGIOMA: RECURRENCE FACTORS Factors predictive of recurrence and functional outcome were determined in a retrospective clinicopathological analysis of 56 patients (26 children and 30 adults) operated on for craniopharyngioma since 1981 at New York University Medical Center. Children underwent gross total resection (GTR) of tumor more frequently than adults (77% cf 27%). Tumors were almost all adamantinomatous in children, whereas in adults, two thirds were adamantinomatous and one third were squamous papillary. Brain invasion was most frequent with the adamantinomatous craniopharyngiomas; invasion had occurred in 46% of the children compared with 17% of adults. Subtotal resection was associated with a higher rate of recurrence compared with total resection. Brain invasion had no effect on recurrence rate in totally resected cases. Functional, visual, and endocrine outcomes were not sacrificed by total resection of tumor. (Weiner HL et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery December 1994;35:1001-1011). (Reprints: Howard L Weiner MD, Dept of Neurosurgery, New York University Medical Center, 550 First Ave, New York, NY 10016). COMMENT. The single most important factor predictive of craniopharyngioma recurrence is the extent of surgical resection. Total compared to subtotal resection has a significantly lower recurrence rate without affecting functional outcome.
    [Show full text]
  • Current Understanding of Neurofibromatosis Type 1, 2, And
    International Journal of Molecular Sciences Review Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis Ryota Tamura Department of Neurosurgery, Kawasaki Municipal Hospital, Shinkawadori, Kanagawa, Kawasaki-ku 210-0013, Japan; [email protected] Abstract: Neurofibromatosis (NF) is a neurocutaneous syndrome characterized by the development of tumors of the central or peripheral nervous system including the brain, spinal cord, organs, skin, and bones. There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in <1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ras/MAPK and PI3K/mTOR signaling pathways. The NF2 gene is identified on chromosome 22q12, which encodes for merlin, a tumor suppressor protein related to ezrin-radixin-moesin that modulates the activity of PI3K/AKT, Raf/MEK/ERK, and mTOR signaling pathways. In contrast, molecular insights on the different forms of SWN remain unclear. Inactivating mutations in the tumor suppressor genes SMARCB1 and LZTR1 are considered responsible for a majority of cases. Recently, treatment strategies to target specific genetic or molecular events involved in their tumorigenesis are developed. This study discusses molecular pathways and related targeted therapies for NF1, NF2, and SWN and reviews recent clinical trials which involve NF patients. Keywords: neurofibromatosis type 1; neurofibromatosis type 2; schwannomatosis; molecular tar- geted therapy; clinical trial Citation: Tamura, R. Current Understanding of Neurofibromatosis Int. Type 1, 2, and Schwannomatosis. 1. Introduction J. Mol. Sci. 2021, 22, 5850. https:// doi.org/10.3390/ijms22115850 Neurofibromatosis (NF) is a genetic disorder that causes multiple tumors on nerve tissues, including brain, spinal cord, and peripheral nerves [1–3].
    [Show full text]
  • 2020 NANETS Guidelines Compendium
    NANETS GUIDELINES 2020 TABLE OF CONTENTS Introduction ............................................................................................................................. 3 NANETS Overview .................................................................................................................... 4 Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors (2020)................................................. 5 Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors (2020) ..................................................................... 34 NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATEPeptide Receptor Radionuclide Therapy (2020) ............................. 83 NANETS/SNMMI Procedure Standard for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE (2019) ............................... 94 The Surgical Management of Small Bowel Neuroendocrine Tumors (2017) ..................................................................... 105 Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors (2017) ................................................... 131 Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors (Joint with SNMMI, 2017) .................................. 143 Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors (2013)............................................................
    [Show full text]